Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management

  • Tony O'Brien
  • , Jin Seok Ahn
  • , Richard Chye
  • , Brian Le
  • , Henry Lu
  • , Gabriel Olarte
  • , Mariana Palladini
  • , Amar Salti
  • , Yu Yun Shao
  • , Hayati Yaakup
  • , Kristal Cielo Buemio
  • , Consuelo Gutierrez Colin
  • , Yacine Hadjiat

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism of action, and safety of buprenorphine. There is also limited guidance on the appropriate use of TDB for chronic pain management. This article presents an overview of TDB and also provides practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain.

Original languageEnglish
Pages (from-to)147-158
Number of pages12
JournalJournal of Opioid Management
Volume15
Issue number2
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Cancer pain
  • Chronic pain management
  • Neuropathic pain
  • Non-cancer pain
  • Practical guide
  • Transdermal buprenorphine

Fingerprint

Dive into the research topics of 'Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management'. Together they form a unique fingerprint.

Cite this